Danaher Corporation $DHR is Arthur M. Cohen & Associates LLC’s 6th Largest Position

Arthur M. Cohen & Associates LLC lessened its position in Danaher Corporation (NYSE:DHR) by 15.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 159,002 shares of the conglomerate’s stock after selling 29,130 shares during the quarter. Danaher accounts for approximately 5.3% of Arthur M. Cohen & Associates LLC’s portfolio, making the stock its 6th largest holding. Arthur M. Cohen & Associates LLC’s holdings in Danaher were worth $31,524,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock valued at $12,004,424,000 after buying an additional 788,499 shares in the last quarter. Geode Capital Management LLC grew its position in Danaher by 0.6% during the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock valued at $2,697,800,000 after acquiring an additional 81,670 shares during the last quarter. Norges Bank purchased a new position in shares of Danaher during the second quarter worth approximately $1,979,503,000. Generation Investment Management LLP lifted its holdings in shares of Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after acquiring an additional 1,787,522 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Danaher by 4.0% in the 2nd quarter. Franklin Resources Inc. now owns 4,822,442 shares of the conglomerate’s stock valued at $952,625,000 after purchasing an additional 186,357 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on DHR shares. Redburn Partners set a $220.00 target price on shares of Danaher in a research report on Wednesday, October 8th. The Goldman Sachs Group assumed coverage on Danaher in a report on Tuesday, December 9th. They issued a “buy” rating and a $265.00 price objective on the stock. Wells Fargo & Company boosted their target price on Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Finally, Robert W. Baird set a $247.00 price target on Danaher in a research note on Wednesday, October 22nd. Twenty-one analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $248.25.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 3,298 shares of Danaher stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the sale, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. The trade was a 13.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 30,248 shares of company stock valued at $6,609,663. Company insiders own 11.20% of the company’s stock.

Danaher Trading Up 0.2%

NYSE DHR opened at $224.78 on Monday. The stock has a market cap of $158.77 billion, a P/E ratio of 46.35, a price-to-earnings-growth ratio of 4.36 and a beta of 0.89. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The stock has a 50 day simple moving average of $220.37 and a two-hundred day simple moving average of $207.11. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the firm earned $1.71 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. On average, analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.